Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 0.64 |
| ▸ | PDE4A | P27815 | 4/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29895373 | 1.00 | PDE4B (0.64) | PDE4BPDE4APDE4CPDE4DPDE7A | |
| SCHEMBL19229992 | 0.92 | PDE4B (0.54) | PDE4B | |
| SCHEMBL28830748 | 0.90 | PDE4B (0.68) | PDE4BPDE4APDE4CPDE4DPDE7A | |
| SCHEMBL19207180 | 0.90 | PDE4B (0.68) | PDE4BPDE4APDE4CPDE4DPDE7A | |
| SCHEMBL20429759 | 0.89 | PDE4B (0.52) | PDE4BPDE4APDE4CPDE4DPDE7A | |
| SCHEMBL17559325 | 0.86 | PDE4B (0.85) | PDE4BPDE4APDE4CPDE4DPDE7A | |
| SCHEMBL18872918 | 0.86 | PDE4B (0.68) | PDE4BPDE4APDE4CPDE4DPDE7A | |
| SCHEMBL29895360 | 0.86 | PDE4B (0.85) | PDE4BPDE4APDE4CPDE4DPDE7A | |
| SCHEMBL16046102 | 0.86 | PDE4B (0.85) | PDE4BPDE4APDE4CPDE4DPDE7A | |
| SCHEMBL20420874 | 0.86 | PDE4B (0.85) | PDE4BPDE4APDE4CPDE4DPDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189044-B1 | CRYSTALLINE (2S)-3-[(3S,4S)-3-[(1R)-1-HYDROXYETHYL]-4-(4-METHOXY-3-{[1-(5-METHYLPYRIDIN-2-YL)AZETIDIN-3-YL]OXY}PHENYL) -3-METHYLPYRROLIDIN-1-YL]-3-OXOPROPANE-1,2-DIOL | LILLY CO ELI (US) | 2018-08-01 | — | — | EP | disclosed |
| US-20170233373-A1 | Crystalline (2S)-3-[(3S,4S)-3-[(1R)-1-hydroxyethyl]-4-(4-methoxy-3-phenyl)-3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol | ELI LILLY AND COMPANY (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2016036596-A1 | CRYSTALLINE (2S)-3-[(3S,4S)-3-[(1R)-1-HYDROXYETHYL]-4-(4-METHOXY-3-{[1-(5-METHYLPYRIDIN-2-YL)AZETIDIN-3-YL]OXY}PHENYL) -3-METHYLPYRROLIDIN-1-YL]-3-OXOPROPANE-1,2-DIOL | ELI LILLY AND COMPANY (US) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016033776-A1 | CRYSTALLINE (2S) -3- [ (3S, 4S) -3- [ (1R) -1-HYDROXYETHYL] -4- (4-METHOXY-3- { [1- (5-METHYLPYRIDIN-2-YL) AZETIDIN-3-YL] OXY} PHENYL) -3-METHYLPYRROLIDIN-1-YL] -3-OXOPROPANE-1, 2-DIOL | ELI LILLY AND COMPANY (US) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233373-A1 | Crystalline (2S)-3-[(3S,4S)-3-[(1R)-1-hydroxyethyl]-4-(4-methoxy-3-phenyl)-3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol | ADRA1D, OPRD1, CHRM3 | PDE4B 69/4885PDE4A 63/4885PDE4C 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.